Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Beth Israel Deaconess Medical Center
- Study ID
- NCT03791060
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Necrobiosis Lipoidica Diabeticorum
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 110 Years
- Healthy Volunteers
- Not accepted
Interventions
- Secukinumab — DRUGSecukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
Study Details
This study investigates the efficacy of secukinumab in necrobiosis lipoidica diabeticorum (NLD).
Key Dates
- Start date
- Apr 3, 2019
- Status verified
- May 2024
- Primary completion
- Jan 17, 2021
- Completion
- Apr 10, 2021
Study Design
- Enrollment
- 4 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Secukinumab Subcutaneous Injection300 mg q weekly for 5 weeks followed by 300 mg q 4 weeks. Each subject will receive 300mg of Secukinumab by using 2 syringes of 150mg each as a subcutaneous injection at weeks 0,1,2,3,4 then every 4 weeks for a total of 9 doses over 24 weeks.
Primary Outcome Measure
Mean Score of Participants Who Received Investigator Global Assessment Scores [ Time Frame: 24 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | - |
Find similar trials in Boston, MA
By research site